- Home
- CABA
CABA
Cabaletta Bio Inc.
as of 02-05-2026 3:55pm EST
$2.31
$0.20
-8.17%
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 212.7M | IPO Year: | 2019 |
| Target Price: | $14.57 | AVG Volume (30 days): | 4.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.99 - $3.67 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered CABA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.68%
69.68%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cabaletta Bio Inc. (CABA)
Binder Gwendolyn
Buy
President, Science & Tech.
CABA Jan 21, 2026
Avg Cost/Share
$2.19
Shares
11,312
Total Value
$24,763.10
Owned After
31,312
SEC Form 4
Gerard Michael
Buy
General Counsel
CABA Jan 21, 2026
Avg Cost/Share
$2.27
Shares
6,600
Total Value
$14,979.36
Owned After
6,600
SEC Form 4
Chang David J.
Buy
Chief Medical Officer
CABA Jan 21, 2026
Avg Cost/Share
$2.26
Shares
8,800
Total Value
$19,888.00
Owned After
8,800
SEC Form 4
Nichtberger Steven
Buy
President & CEO
CABA Jan 21, 2026
Avg Cost/Share
$2.24
Shares
45,000
Total Value
$100,777.50
Owned After
1,031,483
SEC Form 4
Tomasello Shawn
Buy
Director
CABA Jan 21, 2026
Avg Cost/Share
$2.21
Shares
22,725
Total Value
$50,322.24
Owned After
22,725
SEC Form 4
Bollard Catherine
Buy
Director
CABA Jan 21, 2026
Avg Cost/Share
$2.27
Shares
4,405
Total Value
$9,982.17
Owned After
5,405
SEC Form 4
Simon Mark
Buy
Director
CABA Jan 21, 2026
Avg Cost/Share
$2.28
Shares
11,061
Total Value
$25,261.11
Owned After
147,205
SEC Form 4
Gavel Steve
Buy
Chief Commercial Officer
CABA Jan 21, 2026
Avg Cost/Share
$2.27
Shares
22,170
Total Value
$50,215.05
Owned After
22,170
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | CABA | President, Science & Tech. | Jan 21, 2026 | Buy | $2.19 | 11,312 | $24,763.10 | 31,312 | |
| Gerard Michael | CABA | General Counsel | Jan 21, 2026 | Buy | $2.27 | 6,600 | $14,979.36 | 6,600 | |
| Chang David J. | CABA | Chief Medical Officer | Jan 21, 2026 | Buy | $2.26 | 8,800 | $19,888.00 | 8,800 | |
| Nichtberger Steven | CABA | President & CEO | Jan 21, 2026 | Buy | $2.24 | 45,000 | $100,777.50 | 1,031,483 | |
| Tomasello Shawn | CABA | Director | Jan 21, 2026 | Buy | $2.21 | 22,725 | $50,322.24 | 22,725 | |
| Bollard Catherine | CABA | Director | Jan 21, 2026 | Buy | $2.27 | 4,405 | $9,982.17 | 5,405 | |
| Simon Mark | CABA | Director | Jan 21, 2026 | Buy | $2.28 | 11,061 | $25,261.11 | 147,205 | |
| Gavel Steve | CABA | Chief Commercial Officer | Jan 21, 2026 | Buy | $2.27 | 22,170 | $50,215.05 | 22,170 |
Latest Cabaletta Bio Inc. News
CABA Breaking Stock News: Dive into CABA Ticker-Specific Updates for Smart Investing
Argus Research
Daily – Vickers Top Insider Picks for 02/05/2026
Argus Research
Daily – Vickers Top Insider Picks for 02/04/2026
Zacks
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?
📈
AI Sentiment
Highly Positive
9/10
Compare CABA vs Leading Stocks
See how CABA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CABA Cabaletta Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.